SubscribeLatest 5 articles from heartwire
- Sen Grassley questions top medical schools about ghostwriting
Nov 20, 2009 13:15 EDT - Stroke incidence related to PCI steady over 15 years
Nov 20, 2009 13:00 EDT - ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
Nov 19, 2009 14:00 EDT - Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
Nov 19, 2009 11:00 EDT - EFFECT: Public reporting of hospital performance improves quality of care?
Nov 19, 2009 10:00 EDT
Genetic Beta-Blockade
Posted May 07, 2008
at 05:23 PM, EDT
See paper in Nature Medicine, April 20 2008 by Liggett SB et al A GRK polymorphism that inhibits beta-agrenergic receptor signaling is protective in heart failure
Articles:
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure
Previous postsBillets précédents
Ezetimibe in ARBITER 6-HALTS: What lessons can we learn?
No commentsAucun commentaire |
Posted Nov 16, 2009
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
at 05:00 PM, EDT by Eric Publié le 11.16.2009 à 17h00 par Eric
Dabigatran: Crossing a remarkable threshold
No commentsAucun commentaire |
Posted Oct 14, 2009
at 11:00 AM, EDT by Eric Publié le 10.14.2009 à 11h00 par Eric
at 11:00 AM, EDT by Eric Publié le 10.14.2009 à 11h00 par Eric
Antiplatelet therapy: A step forward with individualized medicine
5 comments5 commentaires |
Posted Sep 22, 2009
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
at 10:30 AM, EDT by Eric Publié le 09.22.2009 à 10h30 par Eric
Cash for clunkers, cash for lowering obesity rates
4 comments4 commentaires |
Posted Aug 24, 2009
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
at 01:50 PM, EDT by Eric Publié le 08.24.2009 à 13h50 par Eric
Preventing rehospitalization for heart failure
3 comments3 commentaires |
Posted Jul 28, 2009
at 01:25 PM, EDT by Eric Publié le 07.28.2009 à 13h25 par Eric
at 01:25 PM, EDT by Eric Publié le 07.28.2009 à 13h25 par Eric
Also from theheart.org
Blogs I read
Who's talking
|
Eric J Topol MD
Director, Scripps Translational Science Institute The Gary and Mary West Chair of Innovative Medicine Chief Academic Officer, Scripps Health La Jolla, CA |
CommentsCommentaires
Dear Dr Topol,
As you have been hinting for a long time, the concept of Genotypic Autonomic Modulation accounts for various observations in clinical cardiovascular science including prognosis(1) and drug response. Evidence is apparently accumulating at a fast rate and the current paper is yet another breakthrough. As you would remember, Zaroff et al presented strong prospective evidence of adrenoceptor modulation. They found that specific combinations of adrenoceptor single nucleotide polymorphism (SNP) genotypes can influence the degree of LV dysfunction, myocardial injury and regional WMAs in patients with subarachnoid hemorrhage associated cardiomyopathy.(3,4) Greater clinical research may be promoted targeting an invidualized constituition rather than the usual and somewhat irrational mass-medicine, for the greater good.
References:
1. Heckbert SR, Hindorff LA, Edwards KL, Psaty BM, Lumley T, Siscovick DS, Tang Z, Durda JP, Kronmal RA, Tracy RP. ß2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation 2003; 107: 2021–2024
2. Zaroff JG, Pawlikowska L, Miss JC, Yarlagadda S, Ha C, Achrol A, Kwok PY, McCulloch CE, Lawton MT, Ko N, Smith W, Young WL. Adrenoceptor polymorphisms and the risk of cardiac injury and dysfunction after subarachnoid hemorrhage. Stroke 2006;37:1680-5.
3. Naidech AM. Adrenoreceptor polymorphisms and subarachnoid hemorrhage. Stroke 2006;37:1635.
Hi Dr. Topol, This is a fascinating study that has captured the imagination of much of the cardiovascular community and provides real insights into the future of personal medicine, albeit on a larger scale than the individual patient. Many would argue that the A-HEFT trial was the first study with clinical end-points highlighting the importance of self-reported ethnicity on outcomes. It seems, however, that the first such study may have the BEST trial with bucindolol, in which a sub-analysis (not pre-planned), revealed that bucindolol was not helpful in African-American patients mwith HF. Could this effect have been due to the "genetic beta-blockade"? This is exciting because a RCT in this field with patients of AA descent vs. non-AA descent would be promising...Your thoughts?
Regards,
Ashish Aneja MD
May also explain why blacks seem to get less benefit in BP lowering with beta blockers than whites